WO2007092537A3 - Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same - Google Patents

Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same Download PDF

Info

Publication number
WO2007092537A3
WO2007092537A3 PCT/US2007/003333 US2007003333W WO2007092537A3 WO 2007092537 A3 WO2007092537 A3 WO 2007092537A3 US 2007003333 W US2007003333 W US 2007003333W WO 2007092537 A3 WO2007092537 A3 WO 2007092537A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyperglycosylated
polypeptide
protease
interferon receptor
present
Prior art date
Application number
PCT/US2007/003333
Other languages
French (fr)
Other versions
WO2007092537A2 (en
Inventor
Lawrence M Blatt
Scott D Seiwert
Jin Hong
Original Assignee
Alios Biopharma Inc
Lawrence M Blatt
Scott D Seiwert
Jin Hong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc, Lawrence M Blatt, Scott D Seiwert, Jin Hong filed Critical Alios Biopharma Inc
Priority to EP07763211A priority Critical patent/EP1987060A2/en
Priority to CA002677742A priority patent/CA2677742A1/en
Priority to JP2008554326A priority patent/JP2009526523A/en
Publication of WO2007092537A2 publication Critical patent/WO2007092537A2/en
Publication of WO2007092537A3 publication Critical patent/WO2007092537A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same. The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.
PCT/US2007/003333 2006-02-08 2007-02-07 Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same WO2007092537A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07763211A EP1987060A2 (en) 2006-02-08 2007-02-07 Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
CA002677742A CA2677742A1 (en) 2006-02-08 2007-02-07 Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
JP2008554326A JP2009526523A (en) 2006-02-08 2007-02-07 Synthetic advanced glycosylation, and advanced glycosylation protease resistant polypeptide variants, oral formulations and methods using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/351,163 US7597884B2 (en) 2004-08-09 2006-02-08 Hyperglycosylated polypeptide variants and methods of use
US11/351,163 2006-02-08

Publications (2)

Publication Number Publication Date
WO2007092537A2 WO2007092537A2 (en) 2007-08-16
WO2007092537A3 true WO2007092537A3 (en) 2008-01-24

Family

ID=38180696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003333 WO2007092537A2 (en) 2006-02-08 2007-02-07 Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same

Country Status (5)

Country Link
US (2) US7597884B2 (en)
EP (2) EP2093235A1 (en)
JP (1) JP2009526523A (en)
CA (1) CA2677742A1 (en)
WO (1) WO2007092537A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150881B2 (en) 2009-04-09 2015-10-06 Proteovec Holding, L.L.C. Production of proteins using transposon-based vectors
US9150880B2 (en) 2008-09-25 2015-10-06 Proteovec Holding, L.L.C. Vectors for production of antibodies
US9157097B2 (en) 2008-09-25 2015-10-13 Proteovec Holding, L.L.C. Vectors for production of growth hormone

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005062881A2 (en) * 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
US8092989B2 (en) * 2005-09-15 2012-01-10 Institut Pasteur Targeting the histone code as a bacterial strategy for selectively modulating gene expression
GB0619816D0 (en) * 2006-10-06 2006-11-15 Viragen Inc Novel interferon-alpha constructs for use in the treatment of cancer
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
MX2010008874A (en) 2008-02-14 2010-09-22 Bristol Myers Squibb Co Targeted therapeutics based on engineered proteins that bind egfr.
AR071874A1 (en) 2008-05-22 2010-07-21 Bristol Myers Squibb Co ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE
US20110118183A1 (en) * 2008-06-27 2011-05-19 Novo Nordisk Health Care Ag N-glycosylated human growth hormone with prolonged circulatory half-life
KR101671537B1 (en) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 Multi-arm polymeric alkanoate Conjugates
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
TWI496582B (en) * 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
US8703032B2 (en) 2009-10-14 2014-04-22 Simon Fraser University Biomimetic dry adhesives and methods of production therefor
MX2012005528A (en) * 2009-11-14 2012-06-12 Hoffmann La Roche Biomarkers for predicting rapid response to hcv treatment.
WO2011075605A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated interferon variants and methods of use
WO2011075606A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8895700B2 (en) * 2010-02-18 2014-11-25 Janssen Biotech, Inc. Monkey homolog of human interferon omega
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
ES2573108T3 (en) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Fibronectin-based framework proteins that have improved stability
WO2012037616A1 (en) * 2010-09-24 2012-03-29 Commonwealth Scientific And Industrial Research Organisation Interferon-nu
WO2012051615A1 (en) * 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
TWI557135B (en) 2010-11-03 2016-11-11 介控生化科技公司 Modified factor ix polypeptides and uses thereof
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US9732132B2 (en) 2011-01-14 2017-08-15 Vanderbilt University Therapeutic compositions and methods for disorders associated with neuronal degeneration
JP6220789B2 (en) 2011-10-18 2017-10-25 コヒラス・バイオサイエンシズ・インコーポレイテッド Etanercept formulation stabilized by a combination of sugar and polyol
GB201404403D0 (en) * 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
CA2943241C (en) 2014-03-20 2023-09-19 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
KR20180056701A (en) 2015-09-23 2018-05-29 브리스톨-마이어스 스큅 컴퍼니 Fast-off-rate serum albumin binding fibronectin type III domain
WO2019229480A1 (en) * 2018-06-01 2019-12-05 Alfacyte Limited Compositions and methods relating to the treatment of diseases
CN109485718B (en) * 2018-11-28 2019-08-30 深圳市利云德生物技术有限公司 A kind of new forms of interferon α and preparation method thereof, composition and purposes
WO2020132409A1 (en) * 2018-12-20 2020-06-25 Trustees Of Boston University Stk19 inhibitors for treatment of cancer
EP3901168A1 (en) * 2020-04-21 2021-10-27 Universität Duisburg-Essen Interferon alpha 2 variants and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300475B1 (en) * 1997-12-08 2001-10-09 Genentech, Inc. Interferon PRO655
WO2002081507A2 (en) * 2001-04-06 2002-10-17 Maxygen Holdings Ltd. Interferon gamma polypeptide variants
WO2003066859A2 (en) * 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
WO2004019856A2 (en) * 2002-08-31 2004-03-11 Cj Corp. Glycosylated human interferon alpha isoform

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4042612A (en) 1977-01-03 1977-08-16 Stauffer Chemical Company Polymeric alkoxysilanes
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (en) 1983-12-16 1992-07-01 Genentech Inc RECOMBINANT GAMMA INTERFERONS THAT HAVE IMPROVED STABILITY AND BIOTECHNOLOGICAL METHODS FOR THEIR OBTAINING.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3513726A1 (en) * 1985-04-17 1986-10-23 Basf Ag, 6700 Ludwigshafen METHOD FOR PRODUCING CATALYSTS FOR EXHAUST GAS DETECTING
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
DK173067B1 (en) 1986-06-27 1999-12-13 Univ Washington Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
US4877729A (en) 1986-07-14 1989-10-31 Genetics Institute, Inc. Recombinant DNA encoding novel family of primate hematopoietic growth factors
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4810804A (en) 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
ATE88352T1 (en) 1988-02-26 1993-05-15 Genentech Inc HUMAN RELAXIN PREPARATIVE.
GB8810203D0 (en) 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
US5270198A (en) 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5688666A (en) 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5041376A (en) 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
GB8904009D0 (en) 1989-02-22 1989-04-05 Celltech Ltd Vector
DK111489D0 (en) 1989-03-08 1989-03-08 Novo Nordisk As PEPTIDES
JPH04504858A (en) 1989-04-20 1992-08-27 マウント　シナイ　スクール　オブ　メディスン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク Liver-specific insulin analogs
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0399816B1 (en) 1989-05-24 1995-12-20 Merck & Co. Inc. Purification and characterization of a glioma-derived growth factor
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
ES2055445T3 (en) 1989-08-22 1994-08-16 Immunex Corp FUSION PROTEINS INCLUDING GM-CSF AND IL-3.
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
ES2118756T5 (en) 1990-08-29 2004-01-16 Genetics Institute, Llc HEMATOPOYESIS STIMULATORS OF MULTIPLE DOMAINS.
US5726152A (en) 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU660635B2 (en) 1990-11-16 1995-07-06 Celtrix Pharmaceuticals, Inc. A beta-type transforming growth factor
TW197439B (en) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5736371A (en) 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5302586A (en) 1991-12-19 1994-04-12 G. D. Searle & Co. Phosphonomethyl-imidazo[1,2-a]pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
AU4242993A (en) 1992-05-21 1993-12-13 Penn State Research Foundation, The Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5686268A (en) 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (en) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Process for obtaining 10-deacetyl baccatin III.
FR2696461B1 (en) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa New derivatives of taxol analogs, their preparation and compositions containing them.
FR2696462B1 (en) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Process for obtaining 10-deacetyl baccatin III.
FR2696464B1 (en) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa New esterification process for baccatin III and 10-deacetyl baccatin III.
FR2696458B1 (en) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Process for the preparation of taxane derivatives.
US6214542B1 (en) * 1992-10-20 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services Quantification of indicators of fibrosis
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
FR2704738B1 (en) * 1993-05-06 1997-08-08 Moulinex Sa Household oven.
US5700862A (en) 1993-06-11 1997-12-23 Nippon Paint Co., Ltd. Aqueous coating composition
JP3954091B2 (en) 1993-06-21 2007-08-08 ジェネンテック・インコーポレーテッド Method for producing relaxin
JP3220331B2 (en) 1993-07-20 2001-10-22 エチコン・インコーポレーテツド Absorbable liquid copolymers for parenteral administration
US5728377A (en) 1993-07-20 1998-03-17 Board Of Regents, The University Of Texas System Methods and compositions incorporating IP-10
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US5585250A (en) 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US5426098A (en) 1993-09-02 1995-06-20 Celtrix Pharmaceuticals, Inc. Increase in hematopoietic progenitor cells in peripheral blood by transforming growth factor beta
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
ATE163231T1 (en) 1993-11-23 1998-02-15 Genentech Inc KINASE RECEPTOR ACTIVATION TEST
EP0662515B1 (en) 1993-12-10 2000-11-15 Korea Institute Of Science And Technology Signal sequences for secretion of heterologous proteins from yeast
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5536249A (en) 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5545723A (en) 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5559101A (en) 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5770382A (en) 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
US5770378A (en) 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
US5770383A (en) 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
AR002976A1 (en) 1995-03-31 1998-05-27 Lilly Co Eli PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED
US6491906B1 (en) 1995-06-01 2002-12-10 The Regents Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
ATE455171T1 (en) 1995-09-21 2010-01-15 Genentech Inc VARIANTS OF HUMAN GROWTH HORMONE
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6010203A (en) 1996-07-09 2000-01-04 Brother Kogyo Kabushiki Kaisha Apparatus for recovering an ink jet head and ink jet recorder including the same
CA2262994A1 (en) 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
AU3740997A (en) 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
JP2001501471A (en) * 1996-09-24 2001-02-06 メルク エンド カンパニー インコーポレーテッド Gene therapy for inhibiting angiogenesis
WO1998013495A1 (en) 1996-09-25 1998-04-02 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
CZ123099A3 (en) * 1996-10-09 1999-11-17 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corporation Limited Partnership No. 1 Pharmaceutical preparation for inhibiting stress-activated protein kinases
CA2266889A1 (en) * 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
BR9712544B1 (en) 1996-10-18 2013-10-22 SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
ES2267136T3 (en) 1996-11-21 2007-03-01 Kyowa Hakko Kogyo Kabushiki Kaisha FIT-1 ANTIRRECEPTOR MONOTIONAL ANTIBODY OF HUMAN VEGF.
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
ATE219363T1 (en) 1997-06-20 2002-07-15 Baker Norton Pharma SOLUBLE PRODRUGS OF PACLITAXEL
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
CN1271277A (en) * 1997-07-18 2000-10-25 因菲米德有限公司 Biodegradable macromers fro the controlled release of biologically active substances
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
JP2001526033A (en) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド Human interferon-type I interferon called epsilon
EP1040151A4 (en) 1997-12-12 2003-05-21 Macromed Inc Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification
US6387879B1 (en) * 1997-12-15 2002-05-14 Dgi Biotechnologies, Inc. Compounds that bind growth to hormone receptor
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
JP4549529B2 (en) * 1998-01-30 2010-09-22 サイオス，インコーポレーテッド Controlled release delivery of peptides or proteins
US6221053B1 (en) * 1998-02-20 2001-04-24 Becton, Dickinson And Company Multi-featured medication delivery pen
US5961495A (en) 1998-02-20 1999-10-05 Becton, Dickinson And Company Medication delivery pen having a priming mechanism
WO1999050230A1 (en) 1998-03-31 1999-10-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
BR9910621A (en) * 1998-05-22 2001-01-30 Smithkline Beecham Corp New 2-alkyl imidazole substituted compounds
WO2000006529A1 (en) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (en) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH .
BR9913406A (en) 1998-09-04 2002-01-29 Viropharma Inc Process of treatment of infection caused by at least one virus of the family flaviviridae and of disease associated with said infection in a living host having said infection
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
CA2348822A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
IT1303736B1 (en) * 1998-11-11 2001-02-23 San Raffaele Centro Fond PEPTIDES DERIVED FROM RANTES WITH ANTI-HIV ACTIVITY.
CA2350599A1 (en) 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
ATE275418T1 (en) * 1998-12-17 2004-09-15 Applied Research Systems HUMAN GROWTH HORMONE FOR STIMULATING HEMATOPOASIS AND IMMUNE RECONSTITUTION AFTER HEMATOPOETIC STEM CELL TRANSPLANTATION IN HUMAN BEINGS
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US6703225B1 (en) * 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
PL203797B1 (en) * 1999-04-09 2009-11-30 Ortho Mcneil Pharm Inc Pharmaceutical compositions of erythropoietin
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1183352A1 (en) 1999-05-20 2002-03-06 Scios Inc. Vascular endothelial growth factor variants
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
US6458398B1 (en) 1999-10-18 2002-10-01 Eco Pure Food Safety Systems, Inc. Cold water disinfection of foods
WO2001036001A2 (en) 1999-11-12 2001-05-25 Maxygen Holdings Ltd Interferon gamma conjugates
ID30204A (en) 1999-12-27 2001-11-15 Japan Tobacco Inc COMPOUNDS OF DIFFUSED RING AND ITS USE AS A MEDICINE
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
AU2001234837A1 (en) 2000-02-08 2001-08-20 Schering Corporation Azapeptides useful in the treatment of hepatitis c
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
AU2001261377A1 (en) 2000-05-10 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
EP2329842A3 (en) * 2000-05-12 2011-07-27 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
KR20030001551A (en) 2000-05-22 2003-01-06 레오 파마 에이/에스 Benzophenones as inhibitors of IL-1β and TNF-α
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
DE10031274A1 (en) 2000-06-27 2002-01-10 Bosch Gmbh Robert Wiper arm for motor vehicles
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
BR0115447A (en) 2000-11-20 2005-10-18 Bristol Myers Squibb Co Hepatitis C Tripeptide Inhibitors
WO2002045717A1 (en) 2000-12-06 2002-06-13 Tularik Inc. Lometrexol combination therapy
KR100390943B1 (en) 2000-12-29 2003-07-10 주식회사 하이닉스반도체 Sensing circuit for nonvolatile memory device
RS50236B (en) 2001-01-22 2009-07-15 Merck & Co.Inc., Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US6958388B2 (en) * 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
AU2002338286A1 (en) * 2001-04-10 2002-10-28 Leo Pharma A/S Novel aminophenyl ketone derivatives
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
AR036081A1 (en) 2001-06-07 2004-08-11 Smithkline Beecham Corp COMPOSITE OF 1,2-DIHYDROQUINOLINE, ITS USE TO PREPARE A PHARMACEUTICAL COMPOSITION, METHODS TO PREPARE IT AND N-RENTED 2-AMINOBENZOIC ACID OF UTILITY AS INTERMEDIARY IN SUCH METHODS
FR2825716B1 (en) * 2001-06-11 2004-09-24 Genodyssee NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES FROM IFN ALPHA 7
PL208713B1 (en) 2001-06-11 2011-05-31 Virochem Pharma Inc Thiophene derivatives as antiviral agents for flavivirus infection
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US6585398B1 (en) * 2001-06-22 2003-07-01 Genlyte Thomas Group, Llc Post top deck light fixture
AR035543A1 (en) 2001-06-26 2004-06-16 Japan Tobacco Inc THERAPEUTIC AGENT FOR HEPATITIS C THAT INCLUDES A CONDENSED RING COMPOUND, CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS, BENZIMIDAZOL, THIAZOL AND BIFENYL COMPOUNDS USED AS INTERMEDIARY COMPARTMENTS OF COMPARTMENTS
BR0213093A (en) 2001-10-05 2005-03-15 Intermune Inc Methods for Treatment of Liver Fibrosis and Hepatitis C Virus Infection
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004022747A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20040137581A1 (en) * 2002-10-01 2004-07-15 Xencor Interferon variants with improved properties
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
CA2566677A1 (en) * 2004-05-13 2005-11-24 Intermune, Inc. Combination therapy for treating hepatitis virus infection
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300475B1 (en) * 1997-12-08 2001-10-09 Genentech, Inc. Interferon PRO655
WO2002081507A2 (en) * 2001-04-06 2002-10-17 Maxygen Holdings Ltd. Interferon gamma polypeptide variants
WO2003066859A2 (en) * 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
WO2004019856A2 (en) * 2002-08-31 2004-03-11 Cj Corp. Glycosylated human interferon alpha isoform

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUNKEL L ET AL: "Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-Beta (IFN-Beta)", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 15, no. 4, 1998, pages 641 - 649, XP002271902, ISSN: 0724-8741 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150880B2 (en) 2008-09-25 2015-10-06 Proteovec Holding, L.L.C. Vectors for production of antibodies
US9157097B2 (en) 2008-09-25 2015-10-13 Proteovec Holding, L.L.C. Vectors for production of growth hormone
US9150881B2 (en) 2009-04-09 2015-10-06 Proteovec Holding, L.L.C. Production of proteins using transposon-based vectors

Also Published As

Publication number Publication date
CA2677742A1 (en) 2007-08-16
US7597884B2 (en) 2009-10-06
EP2093235A1 (en) 2009-08-26
US20110008289A1 (en) 2011-01-13
JP2009526523A (en) 2009-07-23
EP1987060A2 (en) 2008-11-05
WO2007092537A2 (en) 2007-08-16
US20060204473A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
WO2007092537A3 (en) Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
WO2006020580A3 (en) Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
CN100384468C (en) L-methionine as a stabilizer for NESP/EPO in hsa-free formulations
MA30474B1 (en) FORMULATIONS OF MOLECULE PEPTIDE (S) - LYOPHILIZED THERAPEUTIC ANTIBODY.
MXPA05009933A (en) Compositions comprising fatty acids and amino acids.
BR9812469A (en) Plasma protein containing pharmaceutical compositions
WO2005070138A3 (en) O-linked glycosylation of peptides
IL210668A (en) Glucagon-like-peptide-2 (glp-2) analogues and pharmaceutical compositions containing them
BRPI0411172A (en) peptide, peptide dimer, its use and pharmaceutical composition
WO2005007185A3 (en) Formulation for a protein pharmaceutical without added human serum albumin (hsa)
ATE425181T1 (en) THERAPEUTIC COMPOSITIONS OF ANTIBODIES AND ANTISENS NUCLEIC ACIDS AGAINST SERRATE
WO2005001038A3 (en) Recombinant anti-cd30 antibodies and uses thereof
BRPI0417342A (en) glycopeguylated granulocyte colony stimulating factor
EP2360258A3 (en) Aprotinin polypeptides for transporting a compound across the blood-brain barrier
BRPI0410164A (en) compositions and methods for preparing human growth hormone glycosylation mutants
WO2001058493A8 (en) Conjugates of follicle stimulating hormones
JP2013504589A5 (en)
EP2272522A3 (en) Therapeutic compositions for use in prophylaxis or treatment of diarrheas
IL194550A (en) Isolated antibody or fragment thereof that binds to human protein tyrosine phosphatase beta, pharmaceutical compositions containing the same and uses thereof
van der Lely et al. Growth hormone receptor antagonists
MXPA05012278A (en) Compositions for delivering peptide yy and pyy agonists.
IL172783A0 (en) Rasgap derived peptide for selectively killing cancer cells
WO2004027064A3 (en) Ghrh analogues
CN107106655A (en) The method that disease and illness are treated using interleukin 10
WO2007025988A3 (en) Liquid formulations of pegylated growth hormone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008554326

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007763211

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2677742

Country of ref document: CA